Stock BEAM BEAM THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
23.13 USD +1.80% Intraday chart for Beam Therapeutics Inc. +8.19% -15.03%
Apr. 04 Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing MT
Apr. 04 Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing MT

Business Summary

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Number of employees: 436

Sales per Business

USD in Million2022Weight2023Weight Delta
Genetic Medicines
100.0 %
61 100.0 % 378 100.0 % +520.01%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
61 100.0 % 378 100.0 % +520.01%

Managers

Managers TitleAgeSince
John Evans CEO
 Chief Executive Officer 46 16-12-31
Giuseppe Ciaramella PSD
 President 55 18-01-31
Terry-Ann Burrell DFI
 Director of Finance/CFO 47 19-07-31
Gopi Shanker CTO
 Chief Tech/Sci/R&D Officer - 23-03-20
Amy Simon CTO
 Chief Tech/Sci/R&D Officer - 21-03-14
Manmohan Singh CTO
 Chief Tech/Sci/R&D Officer 59 18-06-30
Brian Riley PRN
 Corporate Officer/Principal 47 19-08-31
Susan O'Connor HRO
 Human Resources Officer 61 17-07-31
Christine Bellon LAW
 General Counsel - 19-03-31
Suzanne Fleming AUD
 Comptroller/Controller/Auditor 63 19-01-31

Members of the board

Members of the board TitleAgeSince
Graham Cooper BRD
 Director/Board Member 54 19-10-09
John Maraganore BRD
 Director/Board Member 60 21-11-04
Mark Fishman BRD
 Director/Board Member 72 18-04-30
Kristina Burow BRD
 Director/Board Member 50 17-05-31
Kathleen E. Walsh BRD
 Director/Board Member 68 21-01-09
John Evans CEO
 Chief Executive Officer 46 16-12-31
Christi L. Shaw BRD
 Director/Board Member 57 Dec. 13
Carole Ho BRD
 Director/Board Member 51 18-11-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 82,310,167 80,795,167 ( 98.16 %) 0 98.16 %

Shareholders

NameEquities%Valuation
ARK Investment Management LLC
10.02 %
8,182,174 10.02 % 270 M $
Vanguard Fiduciary Trust Co.
8.774 %
7,164,876 8.774 % 237 M $
BlackRock Advisors LLC
7.619 %
6,221,367 7.619 % 206 M $
ARCH Venture Partners LLC
6.666 %
5,443,039 6.666 % 180 M $
STATE STREET CORPORATION
5.653 %
4,616,358 5.653 % 153 M $
Morgan Stanley Investment Management, Inc.
5.124 %
4,184,342 5.124 % 138 M $
Farallon Capital Management LLC
5.028 %
4,105,753 5.028 % 136 M $
Fidelity Management & Research Co. LLC
4.953 %
4,044,811 4.953 % 134 M $
Impresa Management LLC
4.908 %
4,007,424 4.908 % 132 M $
Temasek Holdings Pte Ltd.
3.767 %
3,076,117 3.767 % 102 M $

Holdings

NameEquities%Valuation
PRIME MEDICINE, INC.
1.34%
 1,608,337 1.34% 11,258,359 $

Company contact information

Beam Therapeutics, Inc.

238 Main Street 9th floor

02142-1016, Cambridge

+

http://www.beamtx.com
address Beam Therapeutics Inc.(BEAM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Beam Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
23.13 USD
Average target price
49.54 USD
Spread / Average Target
+114.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BEAM THERAPEUTICS INC. Stock Beam Therapeutics Inc.
-15.03% 1.84B
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. Company Beam Therapeutics Inc.